MiNA Therapeutics secures £10.8m Series A follow-on funding from Eli Lilly and Company to advance its RNA therapeutics pipeline.
Eli Lilly and Company backed the round to support the development of the company's internal pipeline.
MiNA Therapeutics is a biotechnology company pioneering small activating RNA therapeutics to restore or boost normal cell functions. The firm focuses initially on developing treatments for cancer and genetic diseases.
MiNA Therapeutics has secured £10.8m in a Series A follow-on equity investment from Eli Lilly and Company. The funding follows a previous research agreement between the two firms established earlier in the year.
The capital will be directed towards advancing and expanding the company's internal pipeline of small activating RNA therapeutics, with an initial emphasis on immuno-oncology and genetic diseases.
From the founder
"We welcome Lilly as an important shareholder in MiNA. This investment from Lilly, together with our recently announced multi-target research collaboration, represents an important endorsement of our saRNA platform."
Robert Habib
CEO at MiNA Therapeutics
Use of funds
- 01Fund research and development
Investors
Categories
About the company
MiNA Therapeutics
MiNA Therapeutics develops small activating RNA medicines to restore normal cell function.